Number of pages: 100 | Report Format: PDF | Published date: March 17, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
According to the deep-dive market assessment study by Growth Plus Reports, the global post-traumatic stress disorder market was valued at US$ 1.04 billion in 2023 and is expected to register a revenue CAGR of 4.68% to reach US$ 1.51 billion by 2031.
Post-traumatic Stress Disorder Market Fundamentals
Post-traumatic stress disorder (PTSD), also known as shell shock or battle fatigue syndrome, is a serious condition that can develop when a person has experienced a traumatic situation and involves substantial physical damage or threat. PTSD is a long-term effect of traumatic experiences that evoke great fear, helplessness, or terror. Sexual or physical assault, the unexpected loss of a loved one, an accident, war, or natural disaster are some experiences that might trigger PTSD.
PTSD is diagnosed after one month of the stressful incident. To rule out physical disease, the physicians undertake a medical history and physical examination. If no physical ailment is discovered, the patient will be referred to a psychiatrist, psychologist, or another mental health expert who is uniquely qualified to diagnose and treat mental disorders.
PTSD symptoms might occur within one month of a stressful experience but can also appear later. These symptoms produce substantial challenges in social or occupational situations. They can also impair the capacity to carry out daily responsibilities. There are four categories of PTSD symptoms: intrusive memories, avoidance, unfavorable changes in thought and attitude, and changes in physical and emotional reactions. The symptoms may vary from person to person.
Post-traumatic Stress Disorder Market Dynamics
The global post-traumatic stress disorder market is primarily driven by the increasing incidences of PTSD. There are several factors for the increasing prevalence of PTSD, including greater awareness and diagnosis of the condition, a rise in exposure to traumatic events, and an improved understanding of the long-term effects of trauma on mental health. According to Web MD, PTSD affects around 3.6% of adult Americans (5.2 million people) every year. PTSD may occur at any age, even during childhood. Women are more prone than males to suffer PTSD.
The presence of many pipeline drugs for PTSDs is anticipated to help expand the global post-traumatic stress disorder market. For instance, Tonix Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its TNX-102 SL drug had entered phase 2 of clinical trials. TNX-102 SL is a patented sublingual tablet formulation of cyclobenzaprine hydrochloride that allows quick transmucosal absorption and decreased generation of a long half-life active metabolite, norcyclobenzaprine, due to bypass of first-pass hepatic metabolism. Similarly, JZP150 by Jazz Pharmaceuticals is an investigational small molecule being developed for treating PTSD in adults. The drug is currently in phase 2 clinical trials. It is designed to specifically inhibit the enzyme fatty acid amide hydrolase. Fear extinction impairments contribute to the persistence of traumatic memories in those suffering from PTSD.
Collaborations among top players are also driving the global post-traumatic stress disorder market potential. For instance, in September 2022, Sunstone Therapies, a company that treats the psychological effects of cancer, is collaborating with the Multidisciplinary Association for Psychedelics Studies (MAPS) to conduct a clinical trial testing the safety and tolerability of MDMA-assisted therapy for patients with treatment-resistant PTSD. The U.S. Food and Drug Administration (FDA) permitted MAPS to start an enhanced access program for a limited patient group.
However, the side effects of PTSD treatments, such as drug addiction, are projected to limit the revenue growth of the global market during the forecast period.
Post-traumatic Stress Disorder Market Ecosystem
The global post-traumatic stress disorder market is analyzed from five perspectives: drug class, patient type, distribution channel, and region.
Post-traumatic Stress Disorder Market by Drug Class
Based on drug class, the global post-traumatic stress disorder market is segmented into antipsychotics, antidepressants, anti-anxiety, and others.
The antidepressants segment has dominated the global post-traumatic stress disorder market. Antidepressants are effective in reducing the symptoms of PTSD, including anxiety and sleeplessness. They function by altering the levels of neurotransmitters linked to mood regulation and stress response in the brain. In addition, they can benefit patients by enhancing their general quality of life by helping them to lift their moods. Streamline and paroxetine are common antidepressants prescribed to treat PTSD. Moreover, the segment will continue to dominate in the forecast period as antidepressants are recommended as first-line treatment for PTSD.
Moreover, the demand for antipsychotics is also increasing. Antipsychotics have been found to reduce symptoms of anxiety, aggression, and hyperarousal in individuals with PTSD. Additionally, they may improve sleep and overall quality of life for those affected by PTSD.
Post-traumatic Stress Disorder Market by Patient Type
Based on patient type, the global post-traumatic stress disorder market is segmented into children and adults.
The adult segment accounts for the majority of the global post-traumatic stress disorder market revenue share. Adults are more likely to develop PTSD due to exposure to a wider range of traumatic events. Additionally, adults may have a harder time recovering from trauma due to increased responsibilities and stress in their daily lives. According to the U.S. Department of Veterans Affairs, in 2023, around 5 out of every 100 individuals (or 5%) in the United States suffer from PTSD. Around 13 million people were diagnosed with PTSD in 2020. Women are more prone than males to PTSD, which affects around 8 out of every 100 women (or 8%) and 4 out of every 100 males (or 4%). PTSD can have a significant impact on an individual’s daily life, causing symptoms, such as flashbacks, nightmares, and avoidance behaviors. Adults with PTSD need treatment and support to manage their symptoms and improve their quality of life.
However, the children segment is anticipated to increase during the forecast period owing to increasing incidences of PTSD among children. Children experience PTSD due to various traumatic events, such as abuse, neglect, natural disasters, or witnessing violence. PTSD can significantly impact their emotional and behavioral well-being, and early intervention is crucial for their recovery. According to the American Academy of Child and Adolescent Psychiatry, in 2022, about 15%-43% of girls and 14%-43% of boys experience at least one traumatic event. Among them, about 3%-15% of girls and 1%-6% of boys develop PTSD.
Market by Distribution Channel
Based on distribution channel, the global post-traumatic stress disorder market is segmented into hospitals & clinics, home care, and others.
The hospitals & clinics segment accounted for a prominent revenue share of the market in 2022. This is attributed to hospitals and clinics providing better treatment for PTSD due to the advancements in medical research and technology, which have led to the development of more effective therapies and medications. Additionally, there is now a greater understanding of the impact of trauma on mental health, leading to more specialized care for those suffering from PTSD.
Post-traumatic Stress Disorder Market by Region
Based on the region, the global post-traumatic stress disorder market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the post-traumatic stress disorder market with the largest revenue share. This is due to the rising prevalence of PTSD in North America. Additionally, increased research and development efforts and strong and established market competitors throughout the region are boosting revenue growth in the post-traumatic stress disorder market.
Europe accounts for the second-largest market revenue share, owing to increased awareness about therapeutic availability and efficacy, initiatives from government and non-government organizations to strengthen and develop healthcare infrastructure, and a favorable reimbursement system.
Over the forecast period, the Asia Pacific post-traumatic stress disorder market is predicted to develop at the fastest revenue CAGR during the forecast period. The significant growth rate can be due to the increasing disorder burden and the rising number of individuals seeking mental health care from doctors. Government healthcare benefits, increasing population awareness, and a higher desire to seek medical treatment are also projected to help develop the market in Asia Pacific.
Post-traumatic Stress Disorder Market Competitive Landscape
The prominent companies having the largest revenue share in the global post-traumatic stress disorder market are:
Post-traumatic Stress Disorder Market Strategic Developments
The global post-traumatic stress disorder market is expected to grow at a revenue CAGR of 4.68% during the forecast period.
Pfizer, Inc., Aurobindo Pharma Limited, Merck KGaA, and GlaxoSmithKline Plc are among the key players in the global post-traumatic stress disorder market.
The antidepressants segment accounts for the largest revenue share in the global post-traumatic stress disorder market.
Asia Pacific is expected to observe the highest revenue growth during the forecast period.
The global post-traumatic stress disorder market was valued at US$ 1.04 billion in 2023.
*Insights on financial performance are subject to the availability of information in the public domain